{"id":63009,"date":"2026-04-13T20:00:35","date_gmt":"2026-04-13T12:00:35","guid":{"rendered":"https:\/\/flcube.com\/?p=63009"},"modified":"2026-04-13T20:00:36","modified_gmt":"2026-04-13T12:00:36","slug":"hotgen-biotechs-novel-treg-targeting-bispecific-antibody-sgt003-clears-nmpa-filing-hurdle","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63009","title":{"rendered":"Hotgen Biotech&#8217;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle"},"content":{"rendered":"\n<p><strong>Hotgen Biotech Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688068:SHA\">SHA: 688068<\/a>) has announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its clinical trial application for <strong>SGT003<\/strong>, a novel <strong>bispecific antibody (BsAb)<\/strong> candidate. Developed on Hotgen\u2019s proprietary <strong>NexTreg technology platform<\/strong>, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (<strong>Tregs<\/strong>) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Molecule<\/strong><\/td><td>SGT003 (Bispecific Antibody &#8211; BsAb)<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary NexTreg technology<\/td><\/tr><tr><td><strong>Primary Target<\/strong><\/td><td>Regulatory T cells (Tregs) in the tumor microenvironment<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Precise depletion of Tregs to unleash anti-tumor immune response<\/td><\/tr><tr><td><strong>Key Differentiation<\/strong><\/td><td>Aims to reduce immune-related toxicities vs. anti-CTLA-4 (e.g., ipilimumab)<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Broad cohort of solid tumor patients refractory to standard treatments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Immunotherapy Approach:<\/strong> By selectively targeting Tregs\u2014a major barrier to effective anti-tumor immunity\u2014SGT003 represents a next-generation strategy to overcome resistance to existing checkpoint inhibitors.<\/li>\n\n\n\n<li><strong>Improved Safety Profile:<\/strong> The molecule\u2019s design is intended to mitigate the severe immune-related adverse events commonly associated with first-generation CTLA-4 inhibitors like ipilimumab, potentially offering a better therapeutic window.<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> Its mechanism targets a fundamental immunosuppressive pathway, suggesting potential efficacy across a wide range of solid tumor types where Treg infiltration is a known resistance factor.<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> The NMPA filing acceptance is a critical milestone that validates Hotgen\u2019s internal <strong>NexTreg platform<\/strong> and its ability to generate differentiated clinical candidates.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-implications\">Market Context &amp; Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Next-Gen IO Race:<\/strong> The global immuno-oncology field is rapidly evolving beyond PD-1\/CTLA-4. Agents that can safely modulate the tumor microenvironment, like SGT003, are highly sought after.<\/li>\n\n\n\n<li><strong>Chinese Biotech Innovation:<\/strong> This filing highlights the growing sophistication of Chinese biotech firms in developing complex, mechanism-driven biologics with global potential.<\/li>\n\n\n\n<li><strong>Path Forward:<\/strong> With the filing now under review, Hotgen is positioned to initiate its first-in-human clinical trials in China, which will be closely watched for initial safety and proof-of-concept data.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reports on an NMPA filing acceptance. The initiation of clinical trials is subject to further regulatory clearance. The safety and efficacy of SGT003 are unproven, and drug development carries substantial risk of failure at any stage.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688068_20260411_X9JN.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688068_20260411_X9JN.\"><\/object><a id=\"wp-block-file--media-6abc42d3-8f4e-4927-a758-068bd21bf274\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688068_20260411_X9JN.pdf\">688068_20260411_X9JN<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688068_20260411_X9JN.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6abc42d3-8f4e-4927-a758-068bd21bf274\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[90,420,28,1205],"class_list":["post-63009","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-filings","tag-hotgen-biotech","tag-multi-specific-antibodies","tag-sha-688068"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hotgen Biotech&#039;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial application for SGT003, a novel bispecific antibody (BsAb) candidate. Developed on Hotgen\u2019s proprietary NexTreg technology platform, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63009\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hotgen Biotech&#039;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle\" \/>\n<meta property=\"og:description\" content=\"Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial application for SGT003, a novel bispecific antibody (BsAb) candidate. Developed on Hotgen\u2019s proprietary NexTreg technology platform, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63009\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:00:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:00:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63009#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63009\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hotgen Biotech&#8217;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle\",\"datePublished\":\"2026-04-13T12:00:35+00:00\",\"dateModified\":\"2026-04-13T12:00:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63009\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial filings\",\"Hotgen Biotech\",\"Multi-specific antibodies\",\"SHA: 688068\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63009#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63009\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63009\",\"name\":\"Hotgen Biotech's Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T12:00:35+00:00\",\"dateModified\":\"2026-04-13T12:00:36+00:00\",\"description\":\"Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial application for SGT003, a novel bispecific antibody (BsAb) candidate. Developed on Hotgen\u2019s proprietary NexTreg technology platform, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63009#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63009\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63009#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hotgen Biotech&#8217;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hotgen Biotech's Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle - Insight, China&#039;s Pharmaceutical Industry","description":"Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial application for SGT003, a novel bispecific antibody (BsAb) candidate. Developed on Hotgen\u2019s proprietary NexTreg technology platform, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63009","og_locale":"en_US","og_type":"article","og_title":"Hotgen Biotech's Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle","og_description":"Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial application for SGT003, a novel bispecific antibody (BsAb) candidate. Developed on Hotgen\u2019s proprietary NexTreg technology platform, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.","og_url":"https:\/\/flcube.com\/?p=63009","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:00:35+00:00","article_modified_time":"2026-04-13T12:00:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63009#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63009"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hotgen Biotech&#8217;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle","datePublished":"2026-04-13T12:00:35+00:00","dateModified":"2026-04-13T12:00:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63009"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial filings","Hotgen Biotech","Multi-specific antibodies","SHA: 688068"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63009#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63009","url":"https:\/\/flcube.com\/?p=63009","name":"Hotgen Biotech's Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T12:00:35+00:00","dateModified":"2026-04-13T12:00:36+00:00","description":"Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial application for SGT003, a novel bispecific antibody (BsAb) candidate. Developed on Hotgen\u2019s proprietary NexTreg technology platform, SGT003 is designed to precisely deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment to activate anti-tumor immunity in patients with solid tumors resistant to conventional therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63009#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63009"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63009#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hotgen Biotech&#8217;s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63009"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63009\/revisions"}],"predecessor-version":[{"id":63011,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63009\/revisions\/63011"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}